Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)

Introduction: The combination of immune checkpoint inhibitors with chemotherapy is the standard treatment for extensive-stage (ES) SCLC. However, its safety for elderly patients is not fully validated. We evaluated the safety and efficacy of durvalumab plus carboplatin and etoposide in elderly patie...

Cijeli opis

Bibliografski detalji

Glavni autori:	Hidenobu Ishii, MD, PhD, Koichi Azuma, MD, PhD, Yuta Yamanaka, MD, Hiroshige Yoshioka, MD, PhD, Yukihiro Toi, MD, Naoki Shingu, MD, Katsuhiko Naoki, MD, PhD, Masaki Okamoto, MD, PhD, Yuko Tsuchiya-Kawano, MD, PhD, Taishi Harada, MD, Hiroyuki Inoue, MD, PhD, Hiroshi Ishii, MD, PhD, Kazunori Tobino, MD, PhD, Chiho Nakashima, MD, PhD, Yoshifusa Koreeda, MD, Yasushi Hisamatsu, MD, Shinsuke Tsumura, MD, Takashi Inagaki, MD, Keiko Mizuno, MD, PhD, Takayuki Shimose, MMath, Isamu Okamoto, MD, PhD
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-07-01
Serija:	JTO Clinical and Research Reports
Teme:	Small cell lung cancer Durvalumab Elderly Immunotherapy
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2666364325000529
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!